Rasagiline - Neurodegenerative diseases drug- (Jan 2009)
Drug Name:
Rasagiline - Neurodegenerative diseases drug- (Jan 2009)
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Excess dietary tyramine, ciprofloxacin TCADs , tetracycline, pethidine, fluoxetine,fluvoxamine, Dextromethorphan, Sympathomimetics
Indication:
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Rasagiline Mesylate tablet 31-01-2009
0.5mg/1mg
For the signs and symptoms of Idiopathic Parkinsons Disease as initial
monotherapy and as addition to levodopa
Idiopathic Parkinsons disease
Adverse Reaction:
Monotherapy, Headache.Flu-like syndrome. malaise, neck pain Depression, fever, angina,, dyspepsia, flatulence, leucopenia, Arthlagia, arthiritis, musculoskeletal pain, depression,vertigo, hallucinations Rhinitis,conjuntivitis,rash. Skin carcinoma, urinery urgency, Adjuntive therapy, Accidental injury,neck pain postural hypotension, GI upset, constipation, dry mouth, anorexia. Carpral tunnel syndrome, weight loss, dyskinesia, dystonia, Abnormal dreams, balance disorders, hallucinations.
Contra-Indications:
Severe hepatic impairment. During or within 2 weeks of meperidone and MAOIs. Concomitant dextromethorphan. St.Johns wort. Cyclobenzaprine
Special Precautions-
Mild to moderate hepatic impairment. Monitor for melanoma Pregnancy. Lactation
Dosages/ Overdosage Etc:
Idopathic Parkinsons disease
Dosage-
0.5 to 1mg daily as required Patients below 18 years not recommended
Pharmacology/ Pharmacokinetics:
Pharmacology-
Rasagiline is an irreversible monoamine oxidase (MAO) inhibitor indicated for treatment of idiopathic Parkinsons disease. Rasagiline inhibits MAO type B ( MAO- B) but addequate studies to establish whether Rasagiline is selective for Rasagiline for MAO-B in humans have not been conducted
Pharmacokinetics-
Studies have shown that Rasagiline irreversibly inhibits platelet MAO-B . The inhibition lasts for at least 1 week after the last dose. rasagiline is rapidly absorbed reaching peak plasma concentrations Cmax in approx. in 1 hour. The absolute bioavailbility is 36%
Food does affect the time to reach maximum concentration ( Tmax) although Cmax and exposure (AUC) are decreased by approx. by 60% and 20% respy. when taken with a high fat meal Because AUC is not significantly affected, rasagiline can be taken with or without food
Interaction with Food:
Can be taken with or without food
Pregnancy and lactation:
Pregnancy/ Lactation -Exercise caution